Spravato (esketamine) is an FDA-approved nasal spray for treatment-resistant depression (TRD) and major depressive disorder (MDD) with suicidal thoughts. Unlike traditional antidepressants, it works by targeting the brainβs glutamate system. Learn more about how Spravato works in our dedicated guide.
Maintenance Frequency | Patient Response Level |
---|---|
Weekly | Partial responders (25-40% improvement) |
Biweekly | Full responders (>50% improvement) |
Dosage | Frequency | Patient Suitability |
---|---|---|
56 mg | Twice weekly | Initial treatment phase |
84 mg | Weekly/Biweekly | Maintenance phase |
Next Step Psychiatry offers Spravato at multiple Georgia locations:
Many patients report mood improvements within 24-48 hours, though full effects typically develop over 4 weeks.
Most major insurers cover Spravato for TRD. Verify your insurance coverage here.
Ready to explore Spravato treatment? Our compassionate team at Next Step Psychiatry provides:
Schedule Your Consultation:
π² Call: 678-437-1659
π§ Email: info@nextsteppsychiatry.com
π Book Online Now